LENSAR develops and commercializes the LENSAR Laser System, an intelligent laser platform for refractive laser-assisted cataract surgery (ReLACS). The system uses Augmented Reality technology to produce a 3-D model of the eye’s anterior anatomy for customized treatment and precise placement of laser pulses. Led by CEO Nick Curtis, the company is focused on commercializing the LENSAR Laser System across North America, Europe, Asia, Latin America and select markets worldwide. LENSAR intends to use recent financing to support long-term growth, continued commercialization, and development of its hardware- and software-driven platform. The company is based in Orlando, Florida. LensAR is an Orlando, Florida-based developer and supplier of laser and advanced 3D imaging technology for refractive cataract surgery. Its core product is the LensAR™ Laser System, a high-resolution imaging system that produces a high-contrast, low-noise image of the anterior eye in a single scan. The system enables actual correction of lens tilt and provides different centration options during treatment. The LensAR Laser System recently received FDA clearance. The company intends to use the $10M debt facility to commercialize the system. LensAR has treated more than 700 eyes outside the United States to date and is led by CEO Nick Curtis. LensAR develops next-generation laser systems and advanced 3D imaging technology for refractive cataract surgery. Its core product, the LensAR Laser System, pairs a mobile laser head and patient docking with proprietary 3D-CSI imaging to generate personalized surgical treatment plans. Clinical features include measurement of lens tilt and decentration, varied cataract fragmentation algorithms that reduce ultrasound energy, and an ergonomic footprint compatible with typical workflows and multiple operating room layouts. Previous generations of the system have FDA clearance for anterior capsulotomy and lens fragmentation, and the technology has been used in more than 600 eyes outside the United States. The company recently closed a $24 million private financing to support first commercial shipments in the United States, Europe and select markets worldwide and to fund ongoing R&D into additional clinical applications. Management changes announced with the financing include the appointment of Chief Commercial Officer Nick Curtis as interim CEO while former CEO Randy Frey remains on the board and will serve as a consultant. LensAR, Inc. develops and commercializes a next-generation laser system and advanced 3D imaging technology for refractive cataract surgery. The LensAR™ Laser System is FDA-cleared for anterior capsulotomy and lens fragmentation and has been used in more than 500 eyes outside the United States. Topcon Europe Medical BV has made an equity investment in LensAR and entered a long-term strategic cooperation that includes distribution and marketing of the LensAR Laser System in Europe. That cooperation was first announced on September 16, 2011, and the recent announcement ahead of ESCRS in Vienna generated several indication-of-interest deposits toward future delivery upon European commercialization by Topcon. Topcon framed the move as a commitment to technologies that enhance patient outcomes and to integrating LensAR's system with its ocular surgery, implants and diagnostics portfolio. LensAR described the ESCRS reception and the Topcon investment as an endorsement and a commitment to integration and success of the technology in partner physician practices.

Total raised

$121M

Funding rounds

5

Latest round

Equity

Latest activity

Oct 2013